Publications by authors named "M J Lizak"
Acta Neuropathol Commun
April 2024
Article Synopsis
- The blood-tumor barrier (BTB) in malignant glioma limits the effectiveness of cytotoxic drugs, and this study investigates how ibrutinib, a drug already approved for lymphoma, impacts BTB function.
- Ibrutinib was found to dose-dependently reduce brain endothelial cell adhesion and disrupt tight junctions, enhancing penetration of the drug doxil into the tumor and significantly reducing glioma cell viability.
- The combination of ibrutinib and doxil not only improved drug concentration in the brain but also extended the survival of rodent glioma models, highlighting ibrutinib’s potential to enhance therapeutic efficacy in glioma treatment.
